Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2025-01-10 Capital/Financing Update
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
113年12月背書保證與資金貸與
Capital/Financing Update Classification · 90% confidence The document is a financial disclosure from a listed company (美時) providing details about fund loans and endorsement guarantees for the current and previous months, including limits and balances. The content is a regulatory financial update but does not contain comprehensive financial statements or detailed analysis typical of annual or interim reports. It is also not a report publication announcement or certification. The document is short (629 characters) and focuses on specific financial data related to capital and guarantees, which aligns with a Capital/Financing Update rather than a full financial report or other categories.
2025-01-10 Chinese
113年12月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 美時, presented in a tabular format with explanations about accounting standards and reporting practices. It contains no detailed financial statements, management discussion, or comprehensive analysis. The document length is short (779 characters) and it appears to be a brief financial summary rather than a full report. It does not announce a report publication nor is it a certification or legal filing. Given the nature of the content as a brief financial summary, it best fits the category of Fund Information / Factsheet (FS), which is defined as a brief summary of key company facts and financials.
2025-01-10 Chinese
113年12月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, general managers, deputy general managers, and major shareholders. It includes specific data on shares held, increases, decreases, and trust shares. The content focuses on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of a report or announcement of a report, nor is there any mention of financial statements or earnings. This type of document aligns with the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is substantial and contains actual data, not just an announcement or certification. Therefore, the appropriate classification is DIRS with high confidence.
2025-01-09 Chinese
113年12月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, independent directors, senior management, and major shareholders. It lists the number of shares held, pledged shares, and related percentages. The content focuses on insider shareholdings and changes, which aligns with reporting requirements for insider transactions or director dealings. There is no indication of financial results, earnings, management discussion, or regulatory announcements unrelated to insider holdings. The document length is 3655 characters, which is relatively short but contains detailed insider shareholding data. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives. Therefore, the appropriate classification is DIRS.
2025-01-09 Chinese
公告本公司之子公司於1月6日完成越南的 Alphachymotrypsine Choay收購案
Capital/Financing Update Classification · 95% confidence The document is a short announcement (944 characters) about a subsidiary completing an acquisition of a trademark, drug license, and manufacturing technology in Vietnam. It includes details about the transaction and expected sales recognition but does not contain financial statements or detailed financial analysis. The document is a regulatory announcement about a capital transaction related to acquisition activity. It is not a full merger filing or tender offer document but an update on financing/capital structure through acquisition. Therefore, it fits best under Capital/Financing Update (CAP). The document is not a full report, earnings release, or legal proceeding update. Confidence is high due to clear transaction details and nature of announcement.
2025-01-06 Chinese
(補充113/11/07公告)公告本公司任命全球產品組合管理副總經理
Board/Management Information Classification · 100% confidence The document is a company announcement regarding the appointment of a new senior management position, specifically the Global Product Portfolio Management Vice President. It includes details about the new appointee, the effective date, and references a prior board approval. There is no financial data, no report attached or referenced as being published, and no mention of voting results or shareholder meetings. The content clearly fits the category of management changes. Therefore, the document should be classified as Board/Management Information (MANG). The document length is short but contains substantive information about management changes, not just a notice or certification.
2025-01-02 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.